To the Editor: Klawans et al.1 originally reported on the potential use of levodopa loading to predict the presence of the gene for Huntington's disease in at-risk subjects, and an eight-year follow-up study2 demonstrated a prognostic capability for this test. Fahn3 pointed out several problems with provocative testing with levodopa, including the psychological consequences of inducing transient chorea symptoms in subjects, which might result in suicide. He suggested that the ideal test would be one in which the subject would be unaware of the results. Bates,4 however, maintained that the results of presymptomatic tests should not be withheld from.
All Science Journal Classification (ASJC) codes